Trial Profile

A Phase 1, Open-Label Study in Healthy Adults to Evaluate the Safety and Pharmacokinetics of AVYCAZ(R) in Combination With Aztreonam (COMBINE)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avibactam/ceftazidime (Primary) ; Aztreonam (Primary)
Indications Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
Focus Adverse reactions
Acronyms COMBINE

17 Nov 2022 Results evaluating the safety of the optimal ceftazidime-avibactam with aztreonam regimens identified in hollow fiber infection models of MBL producing Enterobacterales published in the Antimicrobial Agents and Chemotherapy
17 Nov 2022 Results assessing Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam in healthy adults published in the Antimicrobial Agents and Chemotherapy
25 Nov 2020 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com